Edesa Biotech (EDSA) Competitors $2.34 -0.09 (-3.70%) (As of 02:41 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EDSA vs. MRKR, PLUR, LGVN, IXHL, PMN, DARE, INKT, RNXT, LSB, and DRRXShould you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Marker Therapeutics (MRKR), Pluri (PLUR), Longeveron (LGVN), Incannex Healthcare (IXHL), ProMIS Neurosciences (PMN), Daré Bioscience (DARE), MiNK Therapeutics (INKT), RenovoRx (RNXT), Lakeshore Biopharma (LSB), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Edesa Biotech vs. Marker Therapeutics Pluri Longeveron Incannex Healthcare ProMIS Neurosciences Daré Bioscience MiNK Therapeutics RenovoRx Lakeshore Biopharma DURECT Edesa Biotech (NASDAQ:EDSA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the media prefer EDSA or MRKR? In the previous week, Marker Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Marker Therapeutics and 0 mentions for Edesa Biotech. Marker Therapeutics' average media sentiment score of 0.96 beat Edesa Biotech's score of 0.62 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Edesa Biotech Positive Marker Therapeutics Positive Is EDSA or MRKR more profitable? Edesa Biotech has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Marker Therapeutics' return on equity of -89.63% beat Edesa Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edesa BiotechN/A -137.95% -97.48% Marker Therapeutics -179.74%-89.63%-71.62% Do analysts rate EDSA or MRKR? Edesa Biotech currently has a consensus price target of $21.00, indicating a potential upside of 797.44%. Marker Therapeutics has a consensus price target of $19.00, indicating a potential upside of 453.94%. Given Edesa Biotech's higher probable upside, equities analysts plainly believe Edesa Biotech is more favorable than Marker Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Marker Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in EDSA or MRKR? 5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by insiders. Comparatively, 17.4% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor EDSA or MRKR? Marker Therapeutics received 45 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote. CompanyUnderperformOutperformEdesa BiotechOutperform Votes2777.14% Underperform Votes822.86% Marker TherapeuticsOutperform Votes7263.72% Underperform Votes4136.28% Which has better valuation & earnings, EDSA or MRKR? Marker Therapeutics has higher revenue and earnings than Edesa Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdesa BiotechN/AN/A-$8.37MN/AN/AMarker Therapeutics$3.31M9.24-$8.24MN/AN/A Which has more volatility and risk, EDSA or MRKR? Edesa Biotech has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. SummaryMarker Therapeutics beats Edesa Biotech on 9 of the 13 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Edesa Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDSA vs. The Competition Export to ExcelMetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.61M$6.69B$5.21B$9.15BDividend YieldN/A8.02%5.73%4.02%P/E RatioN/A6.24103.2414.99Price / SalesN/A324.451,247.4687.66Price / CashN/A56.9841.6838.06Price / Book1.005.314.734.93Net Income-$8.37M$151.54M$119.24M$224.48M7 Day Performance1.74%6.89%2.33%1.69%1 Month Performance-12.69%3.82%1.88%8.93%1 Year Performance-33.14%28.17%31.96%28.19% Edesa Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDSAEdesa Biotech2.5385 of 5 stars$2.34-3.7%$21.00+797.4%-28.1%$7.61MN/A0.0020High Trading VolumeMRKRMarker Therapeutics4.2543 of 5 stars$3.49-0.3%$19.00+444.4%+25.5%$31.13M$3.31M0.0060Positive NewsGap DownPLURPluriN/A$5.52-1.4%N/A+7.9%$30.69M$598,000.00-0.91150LGVNLongeveron3.5891 of 5 stars$2.05flat$8.00+290.2%-90.2%$30.42M$1.89M-0.3323IXHLIncannex Healthcare0.7744 of 5 stars$1.72-3.4%N/A-75.2%$30.35M$86,000.00-1.253News CoveragePMNProMIS Neurosciences1.2789 of 5 stars$0.92-1.9%N/A-19.5%$30.14M$10,000.00-9.406Gap UpDAREDaré Bioscience2.6856 of 5 stars$3.39-1.2%$24.00+608.0%-27.0%$29.49M$2.81M-5.7930Positive NewsINKTMiNK Therapeutics2.1335 of 5 stars$0.74+0.8%$6.50+779.9%-33.9%$29.22MN/A-1.8830Gap UpRNXTRenovoRx1.6733 of 5 stars$1.20-5.5%$6.13+410.4%+83.1%$28.80MN/A-2.216News CoverageGap UpLSBLakeshore Biopharma0.6122 of 5 stars$3.09+12.4%N/AN/A$28.76M$573.42M0.00773Gap DownDRRXDURECT3.5985 of 5 stars$0.92+4.5%$5.00+443.5%+24.8%$28.56M$8.55M-1.5080Analyst ForecastGap Down Related Companies and Tools Related Companies MRKR Competitors PLUR Competitors LGVN Competitors IXHL Competitors PMN Competitors DARE Competitors INKT Competitors RNXT Competitors LSB Competitors DRRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EDSA) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edesa Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edesa Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDSA Stock Alerts